Torrent Picks Up Boehringer Diabetes Brands Ahead Of India Patent Expiry

GLP-1 Generics Coming In 2026

Boehringer Ingelheim’s sale of three diabetes brands in India, with the same composition as Jardiance, Jardiance Met and Glyxambi, to Torrent comes ahead of the expiry of the Indian patent for empagliflozin. A launch for other indications is also expected.

A Business Deal
Torrent And Boehringer Ingelheim Work Out Deal For Anti-Diabetes Brands In India (Shutterstock)

More from Deals

More from Strategy